{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:13:57Z","timestamp":1788779637565,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"DOI":"10.1186\/s12959-026-00890-5","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:48:10Z","timestamp":1782211690000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Two cases of proteasome inhibitors related thrombotic microangiopathies and literature review"],"prefix":"10.1186","volume":"24","author":[{"given":"Na","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"20","key":"890_CR1","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","volume":"125","author":"P Moreau","year":"2015","unstructured":"Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. Blood. 2015;125(20):3076\u201384. https:\/\/doi.org\/10.1182\/blood-2014-09-568915.","journal-title":"Blood"},{"key":"890_CR2","doi-asserted-by":"publisher","first-page":"1088031","DOI":"10.3389\/fphar.2022.1088031","volume":"13","author":"T Mazzierli","year":"2023","unstructured":"Mazzierli T, Allegretta F, Maffini E, Allinovi M. Drug-induced thrombotic microangiopathy: An updated review of causative drugs, pathophysiology, and management. Front Pharmacol. 2023;13:1088031. https:\/\/doi.org\/10.3389\/fphar.2022.1088031.","journal-title":"Front Pharmacol"},{"issue":"9","key":"890_CR3","doi-asserted-by":"publisher","first-page":"E218","DOI":"10.1002\/ajh.25832","volume":"95","author":"MN Nguyen","year":"2020","unstructured":"Nguyen MN, Nayernama A, Jones SC, et al. Proteasome inhibitor-associated thrombotic microangiopathy: A review of cases reported to the FDA adverse event reporting system and published in the literature. Am J Hematol. 2020;95(9):E218\u201322. https:\/\/doi.org\/10.1002\/ajh.25832.","journal-title":"Am J Hematol"},{"issue":"11","key":"890_CR4","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","volume":"98","author":"D Siegel","year":"2013","unstructured":"Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98(11):1753\u201361. https:\/\/doi.org\/10.3324\/haematol.2013.089334.","journal-title":"Haematologica"},{"issue":"4","key":"890_CR5","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1445-5994.2011.02458.x","volume":"41","author":"H Moore","year":"2011","unstructured":"Moore H, Romeril K. Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib. Intern Med J. 2011;41(4):348\u201350. https:\/\/doi.org\/10.1111\/j.1445-5994.2011.02458.x.","journal-title":"Intern Med J"},{"issue":"9","key":"890_CR6","doi-asserted-by":"publisher","first-page":"E348","DOI":"10.1002\/ajh.24447","volume":"91","author":"JC Yui","year":"2016","unstructured":"Yui JC, Van Keer J, Weiss BM, et al. Proteasome inhibitor associated thrombotic microangiopathy. Am J Hematol. 2016;91(9):E348\u201352. https:\/\/doi.org\/10.1002\/ajh.24447.","journal-title":"Am J Hematol"},{"issue":"12","key":"890_CR7","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.3109\/10428190903275586","volume":"50","author":"SA Kumar","year":"2009","unstructured":"Kumar SA, Hu X, Brown M, et al. Lysophosphatidic acid receptor expression in chronic lymphocytic leukemia leads to cell survival mediated though vascular endothelial growth factor expression. Leuk Lymphoma. 2009;50(12):2038\u201348. https:\/\/doi.org\/10.3109\/10428190903275586.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"890_CR8","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/j.cellsig.2007.05.013","volume":"19","author":"K Holmes","year":"2007","unstructured":"Holmes K, Roberts OL, Thomas AM, et al. Vascular endothelial growth factor receptor-2: structure,function,intracellular signalling and therapeutic inhibition. Cell Signal. 2007;19(10):2003\u201312. https:\/\/doi.org\/10.1016\/j.cellsig.2007.05.013.","journal-title":"Cell Signal"},{"issue":"5","key":"890_CR9","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.bbamcr.2012.03.001","volume":"1823","author":"TM Kitzler","year":"2012","unstructured":"Kitzler TM, Papillon J, Guillemette J, et al. Complement modulates the function of the ubiquitin-proteasome system and endoplasmic reticulum-associated degradation in glomerular epithelial cells. Biochim Biophys Acta. 2012;1823(5):1007\u201316. https:\/\/doi.org\/10.1016\/j.bbamcr.2012.03.001.","journal-title":"Biochim Biophys Acta"},{"key":"890_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/978-1-4614-3209-8_31","volume":"801","author":"Z Liu","year":"2014","unstructured":"Liu Z, Qin T, Zhou J, et al. Impairment of the ubiquitin-proteasome pathway in RPE alters the expression of inflammation related genes. Adv Exp Med Biol. 2014;801:237\u201350. https:\/\/doi.org\/10.1007\/978-1-4614-3209-8_31.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"890_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1172\/JCI86418","volume":"127","author":"LS Keir","year":"2017","unstructured":"Keir LS, Firth R, Aponik L, et al. VEGF regulates local inhibitory complement proteins in the eye and kidney. J Clin Invest. 2017;127(1):199\u2013214. https:\/\/doi.org\/10.1172\/JCI86418.","journal-title":"J Clin Invest"},{"issue":"1","key":"890_CR12","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41408-024-01182-9","volume":"14","author":"C Chen","year":"2024","unstructured":"Chen C, Li Y, Shi P, et al. Proteasome inhibitors related thrombotic microangiopathy: a systematic and comprehensive review. Blood Cancer J. 2024;14(1):196. https:\/\/doi.org\/10.1038\/s41408-024-01182-9.","journal-title":"Blood Cancer J"},{"issue":"1","key":"890_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/bjh.16796","volume":"193","author":"M Blasco","year":"2021","unstructured":"Blasco M, Mart\u00ednez-Roca A, Rodr\u00edguez-Lobato LG, et al. Complement as the enabler of carfilzomib-induced thrombotic microangiopathy. Br J Haematol. 2021;193(1):181\u20137. https:\/\/doi.org\/10.1111\/bjh.16796.","journal-title":"Br J Haematol"},{"issue":"3","key":"890_CR14","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1097\/HS9.0000000000000192","volume":"3","author":"V Higuero Saavedra","year":"2019","unstructured":"Higuero Saavedra V, Gonz\u00e1lez-Calle V, Sobejano E, et al. Drug-induced Thrombotic Microangiopathy During Maintenance Treatment in a Patient With Multiple Myeloma. Hemasphere. 2019;3(3):e192. https:\/\/doi.org\/10.1097\/HS9.0000000000000192.","journal-title":"Hemasphere"},{"issue":"12","key":"890_CR15","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.3390\/jcm11123355","volume":"11","author":"E Gavriilaki","year":"2022","unstructured":"Gavriilaki E, Dalampira D, Theodorakakou F, et al. Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls. J Clin Med. 2022;11(12):3355. https:\/\/doi.org\/10.3390\/jcm11123355. Published 2022 Jun 10.","journal-title":"J Clin Med"},{"issue":"1","key":"890_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41408-023-00802-0","volume":"13","author":"M Moscvin","year":"2023","unstructured":"Moscvin M, Liacos CI, Chen T, et al. Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy. Blood Cancer J. 2023;13(1):31. https:\/\/doi.org\/10.1038\/s41408-023-00802-0.","journal-title":"Blood Cancer J"},{"issue":"4","key":"890_CR17","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1016\/j.clml.2020.01.016","volume":"20","author":"D Bhutani","year":"2020","unstructured":"Bhutani D, Assal A, Mapara MY, et al. Case Report: Carfilzomib-induced Thrombotic Microangiopathy With Complement Activation Treated Successfully With Eculizumab. Clin Lymphoma Myeloma Leuk. 2020;20(4):e155\u20137. https:\/\/doi.org\/10.1016\/j.clml.2020.01.016.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"890_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41408-023-00885-9","volume":"13","author":"R Ponraj","year":"2023","unstructured":"Ponraj R, Bryant A, Dunlop L, et al. Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA. Blood Cancer J. 2023;13(1):113. https:\/\/doi.org\/10.1038\/s41408-023-00885-9.","journal-title":"Blood Cancer J"},{"key":"890_CR19","doi-asserted-by":"publisher","first-page":"106195","DOI":"10.1016\/j.leukres.2019.106195","volume":"85","author":"AJ Portuguese","year":"2019","unstructured":"Portuguese AJ, Gleber C, Passero FC Jr, et al. A review of thrombotic microangiopathies in multiple myeloma. Leuk Res. 2019;85:106195. https:\/\/doi.org\/10.1016\/j.leukres.2019.106195.","journal-title":"Leuk Res"},{"issue":"11","key":"890_CR20","doi-asserted-by":"publisher","first-page":"e791","DOI":"10.1016\/j.clml.2020.04.014","volume":"20","author":"BE Monteith","year":"2020","unstructured":"Monteith BE, Venner CP, Reece DE, et al. Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature. Clin Lymphoma Myeloma Leuk. 2020;20(11):e791\u2013800. https:\/\/doi.org\/10.1016\/j.clml.2020.04.014.","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-026-00890-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00890-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00890-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:04:19Z","timestamp":1788779059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12959-026-00890-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["890"],"URL":"https:\/\/doi.org\/10.1186\/s12959-026-00890-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7388047\/v1","asserted-by":"object"}]},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"16 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Our institution does not require ethics approval for reporting individual cases or case series.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Verbal informed consent was obtained from the patient for their information and images to be published anonymously in this article.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"82"}}